Vivian Fonseca, MD
Endocrinology, Diabetes & Metabolism · New Orleans, LANPI 1346356037
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 24.0%. Reporting peaked in 2019 at $211,265 and has fallen 61.5% since, to $81,430 in 2025. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $1229.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$158K
- Asahi Kasei Therapeutics Corporation$87K
- Lilly USA, LLC$82K
- Abbott$81K
- Corcept Therapeutics$70K
- Novo Nordisk$46K
- plus $134K from 30 others
Across 62 payments — averaging $828.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$21K
- Boehringer Ingelheim$17K
- Sanofi-aventis U.S. LLC$9K
- Boehringer Ingelheim Pharma GmbH & Co.kg$5K
- Merck$33
What the payments were for
- Consulting fees$298,77645%
- Speaking & faculty fees$262,03640%
- Travel & lodging$84,28313%
- Food & beverage$12,4452%
- Education$2090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 65 | $157,794 |
| Asahi Kasei Therapeutics Corporation | 6 | $87,000 |
| Lilly USA, LLC | 112 | $82,181 |
| Abbott | 120 | $81,174 |
| Corcept Therapeutics | 68 | $69,679 |
| Novo Nordisk | 34 | $45,781 |
| Takeda | 5 | $25,050 |
| Bayer | 31 | $22,178 |
| Regeneron | 21 | $16,031 |
| Pfizer | 4 | $10,255 |
| Eli Lilly | 6 | $9,600 |
| Beckman Coulter, Inc. | 1 | $6,500 |
| Idorsia Pharmaceuticals US Inc | 6 | $5,614 |
| AstraZeneca | 5 | $5,162 |
| Alfasigma USA, Inc. | 1 | $4,339 |
| Gilead | 5 | $4,243 |
| AbbVie | 1 | $3,875 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $3,540 |
| Scpharmaceuticals Inc. | 2 | $3,132 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,750 |
| Dr.reddy's Laboratories,inc. | 1 | $2,625 |
| Esperion Therapeutics, Inc. | 8 | $2,057 |
| Hikma Pharmaceuticals USA | 1 | $2,000 |
| CSL Behring | 1 | $1,635 |
| Boehringer Ingelheim | 11 | $1,084 |
| Novo Nordisk AS | 2 | $740 |
| Vertex | 1 | $500 |
| Madrigal Pharmaceuticals | 5 | $459 |
| Dexcom, Inc. | 2 | $232 |
| Zealand Pharma US, Inc. | 1 | $189 |
| Astrazeneca UK Limited | 1 | $96 |
| Regeneron Healthcare Solutions, Inc. | 1 | $95 |
| Sanofi | 1 | $90 |
| Amarin Pharma, Inc. | 1 | $35 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$112,912
- Lucica Glycated Albumin-L$87,000
- MOUNJARO$73,716
- Korlym$68,798
- Actos$25,050
- Nesina$25,050
- Edarbi$25,050
- FreeStyle Libre Pro$19,206
- FreeStyle Libre$17,007
- FREESTYLE LIBRE 3$16,433
- SOTAGLIFLOZIN$15,332
- TOUJEO$14,890
- RYBELSUS$13,469
- Kerendia$12,438
- Afinion 2$10,975
- Non-Covered$8,950
- ALERE AFINION HBA1C CONTROL$5,850
- Tryvio$5,483
- LANTUS$5,396
- ADLYXIN$4,790
How this compares
$657,749 in reported general payments places this provider in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 23 | $1,341,677 |
| OzempicSemaglutide | 95 | $141,176 |
| JardianceEmpagliflozin | 138 | $130,245 |
| MounjaroTirzepatide | 85 | $111,580 |
| TrulicityDulaglutide | 67 | $96,353 |
| ForteoTeriparatide | 11 | $45,876 |
| ProliaDenosumab | 20 | $35,011 |
| Cinacalcet Hcl | 34 | $26,197 |
| Teriparatide | 12 | $22,460 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $20,773 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $17,422 |
| FarxigaDapagliflozin Propanediol | 12 | $17,302 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 126 | $15,278 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $14,263 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $13,476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $69,679 | $1,341,67723 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $82,181 | $254,908181 claims |
| Novo NordiskOzempic, Novolog | $45,781 | $143,938113 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,084 | $140,442150 claims |
| AmgenProlia | $14 | $35,01120 claims |
| AstraZenecaFarxiga | $5,162 | $17,30212 claims |
| BayerKerendia | $22,178 | $8,69413 claims |
| AbbVieSynthroid | $3,875 | $1,58919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in New Orleans
- Lawrence BlondeNew Orleans$142K
- Dragana LovreNew Orleans$14K
- Bryan GrissettNew Orleans$8K
- Melina Roman-GerardinoNew Orleans$7K
- Mariam MenhemNew Orleans$5K
- Nyrene HaqueNew Orleans$5K
- Sarah SternliebNew Orleans$2K
- Suneeta GanjiNew Orleans$2K
- Timothy GilbertBaton Rouge$985K
- Abdul KhanHammond$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.